Mariposa: Longer-Term Follow-Up Of Amivantamab & Lazertinib In Egfr-M Nsclc

MARIPOSA: longer-term follow-up of amivantamab & lazertinib in EGFR-m NSCLC

MARIPOSA: follow-up of lazertinib with amivantamab or osimertinib in EGFR-m NSCLC

Amivantamab in patients with EGFR Ex20ins-mutated NSCLC

Post-progression analysis of MARIPOSA-2: amivantamab + chemo in EGFR+ NSCLC

Amivantamab plus lazertinib is a new standard for EGFR-mutant NSCLC

MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in EGFR-mutated NSCLC post-osimertinib

Dr. Gadgeel Discusses Updated MARIPOSA Results at IASLC 2024 World Conference on Lung Cancer

Lung Cancers Today

MARIPOSA-2: second interim OS of amivantamab and chemotherapy in EGFR-m NSCLC

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLC

MARIPOSA: mechanisms of resistance to 1L amivantamab + lazertinib in pts with EGFR-m NSCLC

MARIPOSA Update - Amivantamab + Lazertinib in 1L EGFR mutated metastatic NSCLC.

OncBrothers: Practice-Changing Cancer Discussions

Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2

European Society for Medical Oncology (ESMO)

PALOMA-3: subcutaneous vs intravenous amivantamab + lazertinib in refractory EGFR-mutated NSCLC

The clinical impact of amivantamab and chemotherapy in EGFRm NSCLC

COMBI-AD: long-term follow-up of dabrafenib and trametinib in BRAF-mutated melanoma

New Standard of care Treatment for EGFR Exon 20 Non-small cell Lung Cancer | Dr. Alexander Spira

OncBrothers: Practice-Changing Cancer Discussions

Lung Cancer ESMO 2024 Highlights: Key Studies Discussed LAURA, MARIPOSA, MARIPOSA-2, ADRIATIC

OncBrothers: Practice-Changing Cancer Discussions

Second line treatment in activating EGFR non-small cell lung cancer, MARIPOSA - 2 | Onc Brothers

OncBrothers: Practice-Changing Cancer Discussions

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC

Dr Reckamp on Amivantamab in EGFR Exon 20–Mutated NSCLC